Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00064038 · BASELINE

Baseline characteristics

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma · Source last updated 2015-03-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      97
    2. group Id
      BG001
      value
      95
    3. group Id
      BG002
      value
      192
    units
    Participants
groups
  1. description
    Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Lenalidomide+Dexamethasone
  2. description
    Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
    id
    BG001
    title
    Dexamethasone
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          36.9
          upper Limit
          89.0
          value
          64.9
        2. group Id
          BG001
          lower Limit
          37.6
          upper Limit
          87.0
          value
          63.1
        3. group Id
          BG002
          lower Limit
          36.9
          upper Limit
          89.0
          value
          64.6
      title
      Overall
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          44
        2. group Id
          BG001
          value
          40
        3. group Id
          BG002
          value
          84
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          53
        2. group Id
          BG001
          value
          55
        3. group Id
          BG002
          value
          108
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      97
    2. group Id
      BG001
      value
      95
    3. group Id
      BG002
      value
      192
    units
    Participants
groups
  1. description
    Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Lenalidomide+Dexamethasone
  2. description
    Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
    id
    BG001
    title
    Dexamethasone
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          36.9
          upper Limit
          89.0
          value
          64.9
        2. group Id
          BG001
          lower Limit
          37.6
          upper Limit
          87.0
          value
          63.1
        3. group Id
          BG002
          lower Limit
          36.9
          upper Limit
          89.0
          value
          64.6
      title
      Overall
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          44
        2. group Id
          BG001
          value
          40
        3. group Id
          BG002
          value
          84
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          53
        2. group Id
          BG001
          value
          55
        3. group Id
          BG002
          value
          108
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice